Education
About Us
Working with TipRanks
Follow Us
Dyne Therapeutics (DYN)
NASDAQ:DYN
DYN Stock Chart & Stats
$21.67
-$0.74(-3.10%)
At close: 4:00 PM EST
$21.67
-$0.74(-3.10%)
Day’s Range― - ―
52-Week Range$6.36 - $31.32
Previous CloseN/A
Volume117.44K
Average Volume (3M)2.82M
Market Cap
$3.10B
Enterprise Value$1.12B
Total Cash (Recent Filing)$791.89M
Total Debt (Recent Filing)$21.32M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Feb 26, 2026EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding142,824,690
10 Day Avg. Volume2,170,499
30 Day Avg. Volume2,824,067
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.52
Price to Sales (P/S)0.00
P/FCF Ratio-7.53
Enterprise Value/Market Cap0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.59
Forecast
1Y Price Target
$33.50Price Target Upside54.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.55
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressThe DELIVER trial in the DMD program is on track to report important topline data, which is a promising development for the company.
M&A PotentialThe Avidity acquisition sets a clear benchmark, and Dyne’s more mature dataset strengthens the case for a higher premium takeout.
Strategic PositioningDyne’s dual Breakthrough programs in DM1 and DMD are now entering registrational stages with validated functional and biomarker data, positioning the company as both a clinical catalyst and a strategic M&A asset.
Bears Say
Enrollment DelaysThere is a slight delay in the full enrollment of the DM1 program, now expected in early 2Q26 instead of 4Q25.
Dyne Therapeutics News
DYN FAQ
What was Dyne Therapeutics’s price range in the past 12 months?
Dyne Therapeutics lowest stock price was $6.36 and its highest was $31.32 in the past 12 months.
What is Dyne Therapeutics’s market cap?
Dyne Therapeutics’s market cap is $3.10B.
When is Dyne Therapeutics’s upcoming earnings report date?
Dyne Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 92 days.
How were Dyne Therapeutics’s earnings last quarter?
Dyne Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.837 by $0.077.
Is Dyne Therapeutics overvalued?
According to Wall Street analysts Dyne Therapeutics’s price is currently Undervalued.
Does Dyne Therapeutics pay dividends?
Dyne Therapeutics does not currently pay dividends.
What is Dyne Therapeutics’s EPS estimate?
Dyne Therapeutics’s EPS estimate is -0.78.
How many shares outstanding does Dyne Therapeutics have?
Dyne Therapeutics has 142,824,690 shares outstanding.
What happened to Dyne Therapeutics’s price movement after its last earnings report?
Dyne Therapeutics reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.837. Following the earnings report the stock price went down -12.919%.
Which hedge fund is a major shareholder of Dyne Therapeutics?
Currently, no hedge funds are holding shares in DYN
Dyne Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.50 (54.59% Upside)
$33.50 (54.59% Upside)
Blogger Sentiment
Bullish
DYN Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.01%
12-Months-Change
Fundamentals
Return on Equity
-60.66%
Trailing 12-Months
Asset Growth
12.77%
Trailing 12-Months
Company Description
Dyne Therapeutics
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
DYN Stock 12 Month Forecast
Average Price Target
$33.50
▲(54.59% Upside)
Technical Analysis
Sarepta Therapeutics
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
Currently, No data available
---